Hydroxychloroquine did not prevent illness similar to, or confirmed to be, COVID-19 when used as postexposure prophylaxis within 4 days of moderate- to high-risk exposure, according to findings in The New England Journal of Medicine.“The current public health strategies to mitigate [COVID-19] transmission are rapid identification of cases, isolation, contact tracing and self-quarantine of
In addition to suffering with cystic fibrosis, patients with this condition often contract lung infections that are difficult to treat; however, an upcoming study may…
The FDA has cleared an investigational new drug application for a small molecule therapeutic to treat those with Fragile X syndrome, according to the manufacturer.In…
Approximately 77,000 people in the U.S. have hypoparathyroidism due to absent or subphysiological levels of parathyroid hormone. About 75% of cases are the result of…
ATLANTA — Pregnant women with fewer economic resources may still be at elevated risk for CVD despite a low score on a CVD risk calculator,…
ATLANTA — Data from a small substudy with cardiac MRI suggest acoramidis may improve both cardiac mass and function for adults with symptomatic transthyretin amyloid…
As the eye care world approaches a possible shortage of ophthalmologists, the steady hand of robotic surgical tools could be a welcome addition for patients…
The American Society of Nephrology has called on Congress to increase funding for the U.S. transplant system by $8 million in fiscal year 2025, according…
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV…
BOSTON — More than 40% of patients with difficult-to-treat pathogens were prescribed older, generic agents despite the FDA approval of several new gram-negative antibiotics, findings…
BOSTON — “We should be embracing [AI] and trying to make this a priority to get this right, because I don’t know any alternative to…
